secwatch.observer — SEC 8-K summary
======================================

Issuer:     BOSTON SCIENTIFIC CORP (BSX)
CIK:        0000885725
Form:       8-K
Filed at:   2023-04-26T23:59:59+00:00
Accession:  0000885725-23-000024
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Boston Scientific Q1 beat: sales $3.39B (+14% organic), adj EPS $0.47, guides up
--------------------------------------------------------------------------------

- Q1 net sales $3.389B (+14% organic vs guide 6-8%), GAAP EPS $0.21, adjusted EPS $0.47 vs guide $0.42-0.44.
- Cardiovascular +15.9% operational; MedSurg +13.4%; U.S. +12.7%, EMEA +20% operational.
- FY23 organic sales growth guidance raised to 8-10%; adjusted EPS forecast $1.90-$1.96.
- Q2 guidance: organic sales +7-9%; adjusted EPS $0.48-$0.50.
- Closed acquisitions of Apollo Endosurgery and majority stake in Acotec; FDA clearance for LithoVue Elite.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/885725/000088572523000024/0000885725-23-000024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/885725/000088572523000024/bsx-20230426.htm
  HTML page:      https://secwatch.observer/filing/0000885725-23-000024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer